Saturday, 5 May 2012

Motofen



difenoxin hydrochloride with atropine sulfate

Dosage Form: tablet
Motofen®

Tablets C-IV

(difenoxin hydrochloride with atropine sulfate)

antidiarrheal

Rx only

Motofen Description


Each five-sided dye free Motofen® tablet contains:

Difenoxin (as the hydrochloride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1.0 mg

Atropine Sulfate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .0.025 mg


Difenoxin hydrochloride, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid monohydrochloride, is an orally administered antidiarrheal agent which is chemically related to the narcotic meperidine.


The structural formula is:


Difenoxin Hydrochloride



Atropine sulfate is present to discourage deliberate overdosage.


Atropine sulfate, an anticholinergic, is endo (±)-α-(hydroxymethyl) benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1] oct-3-yl ester sulfate (2:1) (salt) monohydrate and has the following structural formula:



Inactive ingredients: calcium stearate, cellulose, lactose, corn starch.



Motofen - Clinical Pharmacology


Animal studies have shown that difenoxin hydrochloride manifests its antidiarrheal effect by slowing intestinal motility. The mechanism of action is by a local effect on the gastrointestinal wall.


Difenoxin is the principal active metabolite of diphenoxylate.


Following oral administration of Motofen®, difenoxin is rapidly and extensively absorbed. Mean peak plasma levels of approximately 160 ng/mL occurred within 40 to 60 minutes in most patients following an oral dose of 2 mg. Plasma levels decline to less than 10% of their peak values within 24 hours and to less than 1% of their peak values within 72 hours. This decline parallels the appearance of difenoxin and its metabolites in the urine. Difenoxin is metabolized to an inactive hydroxylated metabolite. Both the drug and its metabolites are excreted, mainly as conjugates, in urine and feces.



Indications and Usage for Motofen


Motofen® (difenoxin hydrochloride with atropine sulfate) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.



Contraindications


Motofen® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics. Antiperistaltic agents should not be used in these conditions because they may prolong and/or worsen diarrhea.


Motofen® is contraindicated in children under 2 years of age because of the decreased margin of safety of drugs in this class in younger age groups.


Motofen® is contraindicated in patients with a known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.



Warnings


Motofen® IS NOT AN INNOCUOUS DRUG AND DOSAGE RECOMMENDATIONS SHOULD BE STRICTLY ADHERED TO. Motofen® IS NOT RECOMMENDED FOR CHILDREN UNDER 2 YEARS OF AGE. OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH (SEEOVERDOSAGE). THEREFORE, KEEP THIS MEDICATION OUT OF THE REACH OF CHILDREN.


FLUID AND ELECTROLYTE BALANCE– THE USE OF Motofen® DOES NOT PRECLUDE THE ADMINISTRATION OF APPROPRIATE FLUID AND ELECTROLYTE THERAPY. DEHYDRATION, PARTICULARLY IN CHILDREN, MAY FURTHER INFLUENCE THE VARIABILITY OF RESPONSE TO Motofen® AND MAY PREDISPOSE TO DELAYED DIFENOXIN INTOXICATION. DRUG-INDUCED INHIBITION OF PERISTALSIS MAY RESULT IN FLUID RETENTION IN THE COLON, AND THIS MAY FURTHER AGGRAVATE DEHYDRATION AND ELECTROLYTE IMBALANCE.


IF SEVERE DEHYDRATION OR ELECTROLYTE IMBALANCE IS MANIFESTED, Motofen® SHOULD BE WITHHELD UNTIL APPROPRIATE CORRECTIVE THERAPY HAS BEEN INITIATED.


Ulcerative Colitis – In some patients with acute ulcerative colitis, agents which inhibit intestinal motility or delay intestinal transit time have been reported to induce toxic megacolon. Consequently, patients with acute ulcerative colitis should be carefully observed and Motofen® therapy should be discontinued promptly if abdominal distention occurs or if other untoward symptoms develop.


Liver and Kidney Disease – Motofen® (difenoxin hydrochloride with atropine sulfate) should be used with extreme caution in patients with advanced hepatorenal disease and in all patients with abnormal liver function tests since hepatic coma may be precipitated.


Atropine – A subtherapeutic dose of atropine has been added to difenoxin hydrochloride to discourage deliberate overdosage. Usage of Motofen® in recommended doses is not likely to cause prominent anticholinergic side effects, but Motofen® should be avoided in patients in whom anticholinergic drugs are contraindicated. The warnings and precautions for use of anticholinergic agents should be observed. In children, signs of atropinism may occur even with recommended doses of Motofen®, particularly in patients with Down’s Syndrome.



Precautions



Information for Patients


CAUTION PATIENTS TO ADHERE STRICTLY TO RECOMMENDED DOSAGE SCHEDULES. THE MEDICATION SHOULD BE KEPT OUT OF REACH OF CHILDREN SINCE ACCIDENTAL OVERDOSAGE MAY RESULT IN SEVERE, EVEN FATAL, RESPIRATORY DEPRESSION.


Motofen® may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operating dangerous machinery.



Drug Interactions


Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of Motofen® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis.


Motofen® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. When these medications are used concomitantly with Motofen®, the patient should be closely monitored.


Diphenoxylate hydrochloride, from which the principal active metabolite difenoxin is derived, was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day in studies conducted with male rats. Therefore, difenoxin has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.



Carcinogenesis, Mutagenesis, Impairment of Fertility


No evidence of carcinogenesis was found in a long-term study of difenoxin hydrochloride/atropine in the rat. In this 104 week study, rats received dietary doses of 0, 1.25, 2.5, or 5 mg/kg/day difenoxin/atropine (20:1 ratio).


No experiments have been conducted to determine the mutagenic potential of Motofen®. Motofen® did not significantly impair fertility in rats.



Pregnancy


Teratogenic Effects

Pregnancy Category C. Reproduction studies in rats and rabbits with doses at 31 and 61 times the human therapeutic dose respectively, on a mg/kg basis, demonstrated no evidence of teratogenesis due to Motofen® (difenoxin hydrochloride with atropine sulfate).


Pregnant rats receiving oral doses of difenoxin hydrochloride/atropine 20 times the maximum human dose had an increase in delivery time as well as a significant increase in the percent of stillbirths.


Neonatal survival in rats was also reduced with most deaths occurring within four days of delivery.


There are no well controlled studies in pregnant women. Motofen® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


Because of the potential for serious adverse reactions in nursing infants from Motofen®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use


SAFETY AND EFFECTIVENESS IN CHILDREN BELOW THE AGE OF 12 HAVE NOT BEEN ESTABLISHED. Motofen® IS CONTRAINDICATED IN CHILDREN UNDER 2 YEARS OF AGE. See OVERDOSAGE section for information on hazards from accidental poisoning in children.



Adverse Reactions


In view of the small amount of atropine present (0.025 mg/tablet), such effects such as dryness of the skin and mucous membranes, flushing, hyperthermia, tachycardia and urinary retention are very unlikely to occur, except perhaps in children.


Many of the adverse effects reported during clinical investigation of Motofen® are difficult to distinguish from symptoms associated with the diarrheal syndrome. However, the following events were reported at the stated frequencies:


Gastrointestinal: Nausea, 1 in 15 patients; vomiting, 1 in 30 patients; dry mouth, 1 in 30 patients; epigastric distress, 1 in 100 patients; and constipation, 1 in 300 patients.


Central Nervous System: Dizziness and lightheadedness, 1 in 20 patients; drowsiness, 1 in 25 patients; and headache, 1 in 40 patients; tiredness, nervousness, insomnia and confusion ranged from 1 in 200 to 1 in 600 patients.


Other less frequent reactions: Burning eyes and blurred vision occurred in a few cases.


The following adverse reactions have been reported in patients receiving chemically-related drugs: numbness of extremities, euphoria, depression, sedation, anaphylaxis, angioneurotic edema, urticaria, swelling of the gums, pruritus, toxic megacolon, paralytic ileus, pancreatitis, and anorexia.


THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE REACH OF CHILDREN SINCE AN OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.



Drug Abuse and Dependence


Motofen® (difenoxin hydrochloride with atropine sulfate) tablets are a Schedule IV controlled substance.


Addiction to (dependence on) difenoxin hydrochloride is theoretically possible at high dosage. Therefore, the recommended dosage should not be exceeded. Because of the structural and pharmacological similarities of difenoxin hydrochloride to drugs with a definite addiction potential, Motofen® should be administered with considerable caution to patients who are receiving addicting drugs, to individuals known to be addiction prone, or to those in whom histories suggest may increase the dosage on their own initiative.



Overdosage



Diagnosis and Treatment


In the event of overdosage (initial signs may include dryness of the skin and mucous membranes, flushing, hyperthermia and tachycardia followed by lethargy or coma, hypotonic reflexes, nystagmus, pinpoint pupils and respiratory depression) gastric lavage, establishment of a patent airway and possibly mechanically assisted respiration are advised.


The narcotic antagonist naloxone may be used in the treatment of respiratory depression caused by narcotic analgesics or pharmacologically related compounds such as Motofen® tablets. When naloxone is administered intravenously, the onset of action is generally apparent within two minutes. Naloxone may be administered subcutaneously or intramuscularly providing a slightly less rapid onset of action but a more prolonged effect.


To counteract respiratory depression caused by Motofen® overdosage, the following dosage schedule for naloxone should be followed:


Adult Dosage: The usual initial adult dose of naloxone is 0.4 mg (one mL) administered intravenously. If respiratory function does not adequately improve after the initial dose, the same IV dose may be repeated at two-to-three minute intervals.


Children: The usual adult dose of naloxone for children is 0.01 mg/kg of body weight administered intravenously and repeated at two-to-three minute intervals if necessary.


Since the duration of action of difenoxin hydrochloride is longer than that of naloxone, improvement of respiration following administration may be followed by recurrent respiratory depression. Consequently, continuous observation is necessary until the effect of difenoxin hydrochloride on respiration (which effect may persist for many hours) has passed. Supplemental intramuscular doses of naloxone may be utilized to produce a longer lasting effect. TREAT ALL POSSIBLE Motofen® OVERDOSAGES AS SERIOUS AND MAINTAIN MEDICAL OBSERVATION FOR AT LEAST 48 HOURS, PREFERABLY UNDER CONTINUOUS HOSPITAL CARE.


Although signs of overdosage and respiratory depression may not be evident soon after ingestion of difenoxin hydrochloride, respiratory depression may occur from 12 to 30 hours later.



Motofen Dosage and Administration


The recommended starting dose of Motofen® tablets in adults is 2 tablets (2 mg), then 1 tablet (1 mg) after each loose stool or 1 tablet (1 mg) every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablets (8 mg). In the treatment of diarrhea, if clinical improvement is not observed in 48 hours, continued administration of this type of medication is not recommended. For acute diarrheas and acute exacerbations of functional diarrhea, treatment beyond 48 hours is usually not necessary.


Studies in children below the age of 12 have been inadequate to evaluate the safety and effectiveness of Motofen® in this age group. Motofen® is contraindicated in children under 2 years of age.



How is Motofen Supplied


Motofen® is available as a white, dye-free, five-sided, scored tablet with “0500” on the scored side and “V” on the other side. Each tablet contains 1.0 mg difenoxin (as the hydrochloride salt) and 0.025 mg atropine sulfate. Supplied in bottles of 100 tablets (NDC 0187-0500-02).


Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].


Manufactured for

Valeant Pharmaceuticals North America

One Enterprise

Aliso Viejo, CA 92626 U.S.A.


By West-ward Pharmaceutical Corp.

Eatontown, NJ 07724


Insert printed with food grade ink.


Rev. 01/09



PRINCIPAL DISPLAY PANEL


Motofen Tablets

NDC# 0187-0500-01










Motofen 
difenoxin hydrochloride  tablet










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0187-0500
Route of AdministrationORALDEA ScheduleCIV    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DIFENOXIN HYDROCHLORIDE (DIFENOXIN)DIFENOXIN HYDROCHLORIDE1 mg
ATROPINE SULFATE (ATROPINE)ATROPINE SULFATE0.025 mg












Inactive Ingredients
Ingredient NameStrength
CALCIUM STEARATE 
POWDERED CELLULOSE 
LACTOSE 
STARCH, CORN 


















Product Characteristics
ColorWHITEScore2 pieces
ShapePENTAGON (5 SIDED)Size3mm
FlavorImprint Code0500;V
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10187-0500-02100 TABLET In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01774407/14/1962


Labeler - Valeant Pharmaceutical (042230623)









Establishment
NameAddressID/FEIOperations
West-ward Pharmaceutical Corp001230762MANUFACTURE
Revised: 07/2010Valeant Pharmaceutical

More Motofen resources


  • Motofen Side Effects (in more detail)
  • Motofen Dosage
  • Motofen Use in Pregnancy & Breastfeeding
  • Drug Images
  • Motofen Drug Interactions
  • Motofen Support Group
  • 2 Reviews for Motofen - Add your own review/rating


  • Motofen Advanced Consumer (Micromedex) - Includes Dosage Information

  • Motofen MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Motofen with other medications


  • Diarrhea, Acute
  • Diarrhea, Chronic

Friday, 4 May 2012

Ferrous Sulfate Controlled-Release Capsules



Pronunciation: FER-us SUL-fate
Generic Name: Ferrous Sulfate
Brand Name: Examples include Fe Caps and Slow Fe

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than 6 years old. Keep this product out of the reach of children. In case of an accidental overdose, call a doctor or poison control center right away.





Ferrous Sulfate Controlled-Release Capsules are used for:

Preventing or treating low levels of iron in the blood. It may also be used for other conditions as determined by your doctor.


Ferrous Sulfate Controlled-Release Capsules are an essential body mineral. It works by replacing iron in your body if your body does not produce enough on its own.


Do NOT use Ferrous Sulfate Controlled-Release Capsules if:


  • you are allergic to any ingredient in Ferrous Sulfate Controlled-Release Capsules

  • you have high levels of iron in your blood

Contact your doctor or health care provider right away if any of these apply to you.



Before using Ferrous Sulfate Controlled-Release Capsules:


Some medical conditions may interact with Ferrous Sulfate Controlled-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have inflammation of the intestines, Crohn disease, digestive problems, ulcers, anemia, or a blood disease (eg, porphyria, thalassemia)

  • if you have had multiple blood transfusions

Some MEDICINES MAY INTERACT with Ferrous Sulfate Controlled-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Doxycycline, mycophenolate, penicillamine, or thyroid hormones (eg, levothyroxine) because their effectiveness may be decreased by Ferrous Sulfate Controlled-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Ferrous Sulfate Controlled-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Ferrous Sulfate Controlled-Release Capsules:


Use Ferrous Sulfate Controlled-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Ferrous Sulfate Controlled-Release Capsules by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • Swallow Ferrous Sulfate Controlled-Release Capsules whole. Do not break, crush, or chew before swallowing.

  • Take Ferrous Sulfate Controlled-Release Capsules with a full glass of water (8 oz/240 mL). Do not lie down for 30 minutes after taking Ferrous Sulfate Controlled-Release Capsules.

  • If you are also taking an antacid, a bisphosphonate (eg, alendronate), a cephalosporin (eg, cephalexin), methyldopa, penicillamine, a quinolone (eg, ciprofloxacin), or a tetracycline (eg, minocycline) along with Ferrous Sulfate Controlled-Release Capsules, you may need to space the doses several hours apart. Ask your doctor or pharmacist how much time is needed between doses of Ferrous Sulfate Controlled-Release Capsules and your other medicines.

  • Certain foods and drinks may decrease the amount of Ferrous Sulfate Controlled-Release Capsules that works in your body. Ask your doctor or pharmacist how you should take Ferrous Sulfate Controlled-Release Capsules if you consume whole grain breads or cereal, dairy products, coffee, or tea.

  • If you miss a dose of Ferrous Sulfate Controlled-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ferrous Sulfate Controlled-Release Capsules.



Important safety information:


  • Do not take large doses of vitamins while you use Ferrous Sulfate Controlled-Release Capsules unless your doctor tells you to.

  • Do NOT take more than the recommended dose or take for longer than 6 months without checking with your doctor.

  • Ferrous Sulfate Controlled-Release Capsules has iron in it. Iron overdose is a leading cause of fatal poisoning in children younger than 6 years old. In case of an overdose, call a doctor or poison control center right away.

  • Lab tests, including complete blood cell counts and blood iron levels, may be performed while you use Ferrous Sulfate Controlled-Release Capsules. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Ferrous Sulfate Controlled-Release Capsules should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Ferrous Sulfate Controlled-Release Capsules while you are pregnant. Ferrous Sulfate Controlled-Release Capsules are found in breast milk. If you are or will be breast-feeding while you use Ferrous Sulfate Controlled-Release Capsules, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Ferrous Sulfate Controlled-Release Capsules:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; darkened or green stools; diarrhea; nausea; stomach upset.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; blood or streaks of blood in the stool; fever; vomiting with continuing sharp stomach pain.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Ferrous Sulfate side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include difficulty breathing; loss of consciousness; seizures; severe nausea; stomach pain; tarry stools; unusual tiredness; vomiting; weak, fast heartbeat.


Proper storage of Ferrous Sulfate Controlled-Release Capsules:

Store Ferrous Sulfate Controlled-Release Capsules at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ferrous Sulfate Controlled-Release Capsules out of the reach of children and away from pets.


General information:


  • If you have any questions about Ferrous Sulfate Controlled-Release Capsules, please talk with your doctor, pharmacist, or other health care provider.

  • Ferrous Sulfate Controlled-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Ferrous Sulfate Controlled-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Ferrous Sulfate resources


  • Ferrous Sulfate Side Effects (in more detail)
  • Ferrous Sulfate Use in Pregnancy & Breastfeeding
  • Drug Images
  • Ferrous Sulfate Drug Interactions
  • Ferrous Sulfate Support Group
  • 6 Reviews for Ferrous Sulfate - Add your own review/rating


Compare Ferrous Sulfate with other medications


  • Anemia Associated with Chronic Renal Failure
  • Iron Deficiency Anemia
  • Vitamin/Mineral Supplementation and Deficiency
  • Vitamin/Mineral Supplementation during Pregnancy/Lactation

Wednesday, 2 May 2012

Amitriptyline Tablets BP 10mg





1. Name Of The Medicinal Product



AMITRIPTYLINE TABLETS BP 10mg


2. Qualitative And Quantitative Composition



Each tablet contains 10mg Amitriptyline Hydrochloride.



3. Pharmaceutical Form



Blue film-coated tablets.



4. Clinical Particulars



4.1 Therapeutic Indications



1) Symptoms of depressive illness (especially where sedation is required).



2) Relief of nocturnal enuresis in children.



4.2 Posology And Method Of Administration



Posology



Adults: Initially 50-75mg daily in divided doses or as a single dose at night, increasing to 150-200mg daily according to clinical response.



Maintenance dose 50-100mg at night which should be continued for at least three months to lessen chances of relapse.



Adolescents and the elderly: 25-50mg daily in divided doses or as a single dose at night. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response.



Children: For nocturnal enuresis only. The maximum period of treatment (including gradual withdrawal) should not exceed three months. A further course of treatment should not be started until a full physical examination, including an ECG, has been made.



(11-16 years): 25-50mg daily.



(7-10 years): 10-20mg daily.



(Under 7 years): Not recommended for this age group.



Method of Administration



For oral administration.



4.3 Contraindications



• hypersensitivity to tricyclic antidepressants or to any of the ingredients in the tablets;



• history of myocardial infarction, arrhythmias, particularly heart block to any degree, congestive heart failure, coronary artery insufficiency;



• mania;



• severe liver disease;



• children under 7 years;



• breast feeding;



• patients who are taking monoamine oxidase inhibitors (MAOIs) or have taken them within the last 14 days.



4.4 Special Warnings And Precautions For Use



The elderly are particularly liable to experience adverse reactions, especially agitation, confusion and postural hypotension.



Behavioural changes may occur in children receiving amitriptyline for the treatment of nocturnal enuresis.



Avoid if possible in patients with narrow angle glaucoma, urinary retention, hepatic insufficiency, blood dyscrasias, symptoms suggestive of prostatic hypertrophy and a history of epilepsy. Even average doses may precipitate an attack of glaucoma in patients with narrow-angle glaucoma.



Patients with cardiovascular disorders, hyperthyroid patients and those receiving thyroid medication or anticholinergic drugs should be closely monitored. The dosage of all medications will need to be carefully adjusted.



When used for the depressive component of schizophrenia, amitriptyline should be used with caution as it may aggravate psychotic symptoms. In manic-depressives, a shift towards the manic phase may occur. Paranoid delusions, with or without associated hostility, may be aggravated. A major tranquilliser should be given concurrently in such cases, or dosage of amitriptyline reduced.



Unless essential, it is inadvisable to combine amitriptyline and electroconvulsive therapy (ECT).



Cardiac arrhythmias and severe hypotension are likely to occur with high dosages or in patients with pre-existing heart disease.



If possible, amitriptyline should be discontinued several days before surgery. If emergency surgery is unavoidable, the anaesthetist should be informed that the patient is being treated with amitriptyline (see section 4.5).



Suicide/suicidal thoughts or clinical worsening



Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.



Suicidal thoughts and behaviours may also develop during early treatment with antidepressants for other disorders, the same precautions observed when treating patients with depression should therefore be followed when treating patients with other disorders.



Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.



Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Alcohol: Enhances the sedative effect.



Alpha2-adrenoceptor stimulants: Concomitant use of apraclonidine and brimonidine should be avoided.



Altretamine: Risk of severe postural hypotension.



Anaesthetics: Concomitant therapy may increase the risk of arrhythmias and hypotension. If surgery is necessary, the anaesthetist should be informed that a patient is being so treated (see section 4.4).



Analgesics: There is a possibility of increased side effects with nefopam. The risk of CNS toxicity is increased with tramadol. There is a possibility of increased sedation with opioid analgesics.



Anti-arrhythmics: there is an increased risk of ventricular arrhythmias with drugs which prolong the QT interval, including amiodarone (avoid concomitant use), disopyramide, procainamide, propafenone and quinidine.



Antibacterials: Plasma concentrations of some tricyclics are reduced by rifampicin (reduces antidepressant effect). Concomitant use with linezolid may result in CNS excitation and hypertension.



Anticholinergics: Excessive anticholinergic effects may occur when tricyclic antidepressants are combined with anticholinergic drugs. Paralytic ileus, urinary retention or acute glaucoma may be precipitated, especially in elderly patients.



Antidepressants: Concomitant use with MAOIs results in CNS excitation and hypertension. Severe convulsions and fatalities have occurred. Therefore, amitriptyline should not be given with a MAOI, and a minimum of 14 days should elapse between discontinuing a MAOI and starting amitriptyline. After this time, amitriptyline should be used cautiously and dosage increased gradually. Concomitant use of reboxetine should be with caution. The plasma concentrations of some tricyclics are increased by SSRIs. Fluoxetine markedly inhibits Cytochrome P450 II D6, which is involved in the metabolism of a number of tricyclic antidepressants. Patients should be monitored for increased antidepressant plasma levels and toxicity when fluoxetine is used concurrently. Adjustment of the antidepressant dosage may be necessary.



Antiepileptics: Concomitant use of antiepileptics may lower the convulsive threshold. The plasma concentrations of some tricyclics may be reduced (eg by barbiturates, carbamazepine) resulting in reduced antidepressant effect.



Antifungals: Increased serum concentraions have occurred in patients also taking Fluconazole. Serious adverse effects have been reported due to increased amitriptyline plasma concentration.



Antihistamines: Increased anticholinergic and sedative effects. Concomitant use of terfenadine should be avoided due the increased risk of ventricular arrhythmias.



Antihypertensives: In general, the hypotensive effect is enhanced, but the effect of adrenergic neurone blockers (eg guanethidine, debrisoquine, bethanidine) and clonidine may be antagonised. There is an increased risk of hypertension on clonidine withdrawal. It is advisable to review all antihypertensive therapy during treatment with tricyclic antidepressants.



Antipsychotics: Increased risk of ventricular arrhythmias. Avoid concomitant use with pimozide or thioridazine. Concomitant use with antipsychotics may increase plasma concentrations of tricyclic antidepressants and increase the anticholinergic side-effects of phenothiazines and possibly clozapine.



Antivirals: Based on the known metabolism of amitriptyline, the protease inhibitor, ritonavir, may increase the serum levels of amitriptyline. Therefore, careful monitoring of therapeutic and adverse effects is recommended when these drugs are administered concomitantly.



Anxiolytics and hypnotics: Concomitant use enhances the sedative effect. Caution is advised if patients receive large doses of ethchlorvynol concurrently. Transient delirium has been reported in patients treated with 1g ethchlorvynol and 75mg to 150mg of amitriptyline.



Beta-blockers: There is an increased risk of ventricular arrhythmias associated with concomitant use of sotalol.



Calcium-channel blockers: Diltiazem and verapamil may possibly increase the plasma concentration of amitriptyline.



Disulfiram: Concomitant use may inhibit the metabolism of tricyclics. Delirium has been reported in patients taking amitriptyline with disulfiram.



Diuretics: increased risk of postural hypotension.



Dopaminergics: Concomitant use with entacapone should be avoided. CNS toxicity has been reported with selegiline.



Muscle relaxants: Concomitant use of baclofen enhances its muscle relaxant effect.



Nitrates: Reduced effect of sublingual nitrates (owing to dry mouth).



Oestrogens and progestogens: Oral contraceptives antagonise the antidepressant effect but side-effects may be increased due to increased plasma concentrations of tricyclics.



Sibutramine: Concomitant use is not recommended due to the increased risk of CNS toxicity.



Sympathomimetics: Amitriptyline should not be given with sympathomimetic agents such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine due to hypertension and arrhythmias. Local anaesthetics with adrenaline appear to be safe. Methylphenidate may inhibit the metabolism of tricyclics and therefore increase the antidepressant action of amitriptyline.



Ulcer-healing drugs: Plasma concentrations of amitriptyline are increased by cimetidine (inhibition of metabolism).



4.6 Pregnancy And Lactation



The safety of amitriptyline during pregnancy and lactation has not been established. Amitriptyline should not be used during the first and third trimester and the hazards to the foetus, child or mother must be evaluated when considering the possible benefits of amitriptyline therapy during pregnancy. Clinical experience of the use of amitriptyline in pregnancy is limited. Animal studies have shown harmful effects at exceptionally high doses. Withdrawal symptoms, including respiratory depression and agitation have been reported in neonates whose mothers had taken tricyclic antidepressants during the last trimester of pregnancy. Urinary retention in the neonate has also been associated with maternal use of amitriptyline.



Amitriptyline is detectable in breast milk at high doses. Because of the potential for serious adverse reactions in infants from amitriptyline, a decision should be made whether to discontinue breast-feeding or discontinue the drug.



4.7 Effects On Ability To Drive And Use Machines



Amitriptyline may initially impair alertness. Patients should be warned of the performance of potentially hazardous tasks such as driving a car or operating machinery.



4.8 Undesirable Effects



In general, amitriptyline is well tolerated. Not all of the side-effects listed below have been reported with amitriptyline but are included due to the similar pharmacology of other tricyclics. Antidepressant effects of amitriptyline may not become apparent for the first 2-4 weeks of therapy so patients should be closely monitored during this period.



Allergic reactions: Skin rashes, urticaria, photosensitisation, oedema of face and tongue.



Blood and lymphatic system disorders: Bone marrow depression including agranulocytosis, eosinophilia, leucopenia, thrombocytopenia and purpura.



Endocrine disorders: Gynaecomastia, breast enlargement, galactorrhoea, testicular swelling, libido fluctuations, interference with sexual function, syndrome of inappropriate ADH secretion.



Metabolism and nutrition disorders: Elevation or lowering of blood sugar levels. Increased appetite and weight gain may be a drug reaction or due to relief of depression.



Nervous system disorders: Dizziness, fatigue, headache, drowsiness, weakness, disturbed concentration, disorientation, confusional states, insomnia, nightmares, delusions, hallucinations, hypomania, excitement, anxiety, restlessness, peripheral neuropathy, numbness, tingling and paraesthesia of the extremities, inco-ordination, ataxia, tremors, convulsions, altered ECG, extrapyramidal effects, tinnitus. Cases of suicidal ideation and suicidal behaviours have been reported during Amitriptyline therapy or early after treatment discontinuation (see section 4.4). Anticholinergic effects include: dry mouth, hyperpyrexia, blurred vision, accommodation disturbance, increased intra-ocular pressure, mydriasis, constipation, paralytic ileus, urinary retention, urinary tract dilatation.



Cardiovascular disorders: Postural hypotension, hypertension, palpitations, or tachycardia, myocardial infarction, heart block and stroke. Arrhythmias and severe hypotension are likely to occur with high doses or overdosage.



Gastrointestinal disorders: Nausea, vomiting, diarrhoea, epigastric distress, anorexia, dysgeusia, stomatitis, parotid swelling, black tongue.



Hepato-biliary disorders: Rarely hepatitis (including altered liver function and jaundice).



Skin and subcutaneous tissue disorders: Increased perspiration and alopecia.



Renal and urinary disorders: Urinary frequency.



Class effects



Epidemiological studies show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this increased risk is unknown.



Abrupt withdrawal after prolonged administration has caused nausea, headache and malaise. Gradual withdrawal has been associated with transient symptoms such as dream and sleep disturbances, irritability and restlessness during the first two weeks of dosage reduction. These are not thought to be signs associated with addiction.



Mania or hypomania have been reported rarely within 2-7 days of stopping therapy with tricyclic antidepressants.



Side-effects in enuresis: As dosages used in enuresis are low compared to those used for depression, side-effects are less frequent. The most common are drowsiness and anticholinergic effects. Infrequently, mild sweating and itching have been reported. Behavioural changes have been observed in children receiving tricyclics for treatment of enuresis.



4.9 Overdose



There is no specific antidote for tricyclic antidepressant poisoning. Patients should be hospitalised and treatment should be symptomatic and based on cardiac (including ECG monitoring) and respiratory support.



Symptoms



Toxicity is due to a combination of anticholinergic (antimuscarinic, atropine-like) effects at autonomic nerve endings and in the brain, cardiac sodium channel blockade and a1 adrenergic receptor blockade. In addition, tricyclic antidepressants block pre-synaptic uptake of amines and the cardiac delayed rectifier potassium channel (Ikr).



Features commonly include: sinus tachycardia, hot dry skin, dry mouth and tongue, dilated pupils, urinary retention and ileus, progressing to ataxia, nystagmus, divergent squint and drowsiness which may lead to deep coma and respiratory depression. Increased tone and hyperreflexia may be present with extensor plantar reflexes. In deep coma all reflexes (including brain-stem reflexes) may be abolished. Convulsions occur in >5% of cases and may herald haemodynamic compromise.



ECG features include prolongation of the PR, QRS and QT intervals, non-specific ST segment and T wave changes and atrioventricular block.



Metabolic acidosis may be present. Hypotension may occur and may be severe.



Hypothermia and rhabdomyolysis may occur in patients who have been unconscious. Occasionally skin blisters may occur.



During recovery confusion, agitation and visual hallucinations may occur.



Features of serotonin toxicity may occur. These include CNS effects (including agitation or coma), autonomic instability (including hyperpyrexia), and neuromuscular excitability (including clonus and raised serum creatine kinase)



This syndrome is more likely to occur if the patient has been exposed to two or more drugs that increase the effect of serotonin in serotonergic synapses (by increasing release, reducing reuptake or metabolism, or stimulating serotonin receptors), either as an acute overdose or if taken regularly, for example - SSRIs, MAOIs, tricyclic antidepressants, venlafaxine, tramadol, triptans, linezolid and St John's Wort; stimulant drugs of abuse (e.g. MDMA (ecstasy), amphetamines, cocaine, cathinone derivatives (mephedrone, etc)).



The cardiovascular and CNS effects in overdose will be potentiated by simultaneous ingestion of alcohol, cardiovascular agents and other psychotropic drugs



Management



Do not give flumazenil to reverse benzodiazepine toxicity in mixed overdoses.



1. Ensure a clear airway and adequate ventilation. Check arterial blood gases and correct any hypoxia. If hypercapnia is present assisted ventilation is indicated.



2. The benefit of gastric decontamination is uncertain. Consider activated charcoal by mouth or naso-gastric tube if the patient presents within 1 hour of ingestion of more than 5mg/kg, provided the airway can be protected.



A second dose of charcoal should be considered after 1 -2 hours in patients with features of toxicity who are able to swallow, or who have been intubated.



3. After cardiac arrest, prolonged resuscitation may be successful and should be continued for at least 1 hour.



4. Observe for at least 6 hours after ingestion. Monitor BP, pulse and cardiac rhythm. Repeat ECGs should be performed. Patients who remain asymptomatic and have a normal ECG by 6 hours are unlikely to develop late complications.



5. Check urea and electrolytes and monitor urine output. Check serum creatine kinase in patients who have been unconscious.



6. If metabolic acidosis persists despite correction of hypoxia and adequate fluid resuscitation consider correction with intravenous sodium bicarbonate. Rapid correction is particularly important if there is prolongation of the QRS or QT intervals.



7. Control convulsions with intravenous diazepam or lorazpam. Give oxygen and correct acid base and metabolic disturbances. Phenytoin is contraindicated in tricyclic overdosage (because in common with TCAs it blocks sodium channels and may increase the risk of cardiac arrhythmias).



8. Correct hypotension by raising the foot of the bed. In severe cases administration of colloid to expand the intravascular volume is required (central venous pressure monitoring may be required). Alkalinisation with sodium bicarbonate may correct hypotension.



9. Agitated adults can be sedated with oral or IV diazepam. If ineffective consider oral or parenteral haloperidol.



10. Glucagon 10mg IV bolus may be given if patients are severely hypotensive.



11. If the patient is hypothermic, rewarm slowly using conventional means.



12. Monitor for rhabdomyolysis if the patient has been unconscious for a considerable time.



13. Forced diuresis, haemodialysis and haemoperfusion are of no value due to the large volume of distribution of tricyclic antidepressants.



14. Other measures as indicated by the patient's clinical condition.



For further information or treatment in children discuss with your local poisons information service: in the UK NPIS 0844 892 0111, in Ireland NPIC (01) 809 2566.



Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Deaths by deliberate or accidental overdosage have occurred with this class of medicament.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Amitriptyline hydrochloride is a tricyclic antidepressant.



5.2 Pharmacokinetic Properties



Amitriptyline is readily absorbed from the GI tract, peak plasma levels occurring within approximately 6 hours of oral administration. Amitriptyline is extensively demethylated in the liver to its primary metabolite, nortriptyline. Paths of metabolism include hydroxylation, N-oxidation and conjugation with glucuronic acid. It is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



The tablets also contain: lactose monohydrate, microcrystalline cellulose (E460), maize starch, colloidal anhydrous silica, magnesium stearate.



The coating contains: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), macrogol, indigo carmine (E132).



6.2 Incompatibilities



None known.



6.3 Shelf Life



Shelf-life



A three year shelf-life is claimed and our marketed products includes a three year expiry date.



Shelf-life after dilution/reconstitution



Not applicable.



Shelf-life after first opening



Not applicable.



6.4 Special Precautions For Storage



Store below 25°C in a dry place. Protect from light.



6.5 Nature And Contents Of Container



The product containers are rigid injection moulded polypropylene or injection blow-moulded polyethylene containers and snap-on polyethylene lids; in case any supply difficulties should arise the alternative is amber glass containers with screw caps.



Container pack sizes: 28s, 30s, 56s, 60s, 84s, 90s, 100s, 112s, 120s, 168s, 180s, 250s, 500s, 1000s



The product may also be supplied in blister packs in cartons:



a) Carton: Printed carton manufactured from white folding box board.



b) Blister pack: (i) 250µm white rigid PVC. (ii) Surface printed 20µm hard temper aluminium foil with 5-6g/M² PVC and PVdC compatible heat seal lacquer on the reverse side.



Blister pack sizes: 28s, 30s, 56s, 60s, 84s, 90s, 98s, 100s, 112s, 120s, 168s, 180s, 250s, 500s, 1000s



Product may also be supplied in bulk packs, for reassembly purposes only, in polybags contained in tins, skillets or polybuckets filled with suitable cushioning material. Bulk packs are included for temporary storage of the finished product before final packaging into the proposed marketing containers.



Maximum size of bulk packs: 50,000.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



Administrative Data


7. Marketing Authorisation Holder



Actavis UK Limited



(Trading style: Actavis)



Whiddon Valley



BARNSTAPLE



N Devon EX32 8NS



8. Marketing Authorisation Number(S)



PL 0142/0176



9. Date Of First Authorisation/Renewal Of The Authorisation



17.4.84



Renewed: 29.10.02



10. Date Of Revision Of The Text



22/02/2011




Tobramycin Solution



Pronunciation: TOE-bra-MYE-sin
Generic Name: Tobramycin
Brand Name: Tobi


Tobramycin Solution is used for:

Treating patients with cystic fibrosis and certain infections (Pseudomonas aeruginosa). It may also be used for other conditions as determined by your doctor.


Tobramycin Solution is an aminoglycoside antibiotic. It works by killing sensitive bacteria.


Do NOT use Tobramycin Solution if:


  • you are allergic to any ingredient in Tobramycin Solution or another aminoglycoside antibiotic (eg, gentamicin)

  • you are taking loop diuretics (eg, furosemide, ethacrynic acid), cyclosporine, mannitol, methoxyflurane, nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), or urea

Contact your doctor or health care provider right away if any of these apply to you.



Before using Tobramycin Solution:


Some medical conditions may interact with Tobramycin Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have myasthenia gravis (a condition in which the muscles become progressively paralyzed) or Parkinson disease

  • if you have hearing problems, nerve problems, kidney problems, or severe or extensive burns, or you are dehydrated

Some MEDICINES MAY INTERACT with Tobramycin Solution. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Aminoglycosides (eg, gentamicin), cephaloridine, cisplatin, colistin, cyclosporine, fludarabine, loop diuretics (eg, furosemide, ethacrynic acid), mannitol, methoxyflurane, nitrosoureas (eg, carmustine), NSAIDs (eg, ibuprofen), polymyxin B, urea, vancomycin, or viomycin because they may increase the risk of Tobramycin Solution's side effects, including increased risk of kidney or hearing loss

  • Beta-lactam antibiotics (eg, penicillin, imipenem, ceftizoxime) because they may decrease Tobramycin Solution's effectiveness

  • Nondepolarizing muscle relaxants (eg, atracurium) or succinylcholine because the risk of their side effects may be increased by Tobramycin Solution

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tobramycin Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Tobramycin Solution:


Use Tobramycin Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • An extra patient leaflet is available with Tobramycin Solution. Talk to your pharmacist if you have questions about this information. Read it carefully for instructions on how to prepare Tobramycin Solution for inhalation, administer it, clean and disinfect your nebulizer, and care for your Pulmo-Aide Compressor. Talk to your pharmacist if you have questions about this information.

  • If you are also using dornase alfa, do not mix Tobramycin Solution in the same nebulizer as the dornase alfa.

  • If you are taking several inhaled medicines, talk to your doctor about the best order for taking your medicines.

  • Tobramycin Solution is normally slightly yellow in color and may darken with age if it has been left out of the refrigerator. This will not change the effectiveness of Tobramycin Solution.

  • Do not use Tobramycin Solution if it is cloudy, contains particles, or if it has been stored at room temperature for more than 28 days.

  • Tobramycin Solution is usually used in cycles of 28 days on the medicine followed by 28 days off the medicine. Follow the dosing schedule given to you by your doctor carefully.

  • Use your doses as close to 12 hours apart as possible.

  • If you miss a dose of Tobramycin Solution, use it as soon as possible. If it is less than 6 hours until your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Tobramycin Solution.



Important safety information:


  • Tobramycin Solution only works against bacteria; it does not treat viral infections (eg, the common cold).

  • Drinking extra fluids while you are using Tobramycin Solution is recommended. Check with your doctor for instructions.

  • If severe diarrhea, stomach pain or cramping, or bloody stools develop during treatment or within several months after treatment with Tobramycin Solution, check with your doctor or pharmacist right away. Do not treat it without first checking with your doctor.

  • Be sure to use Tobramycin Solution for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • Long-term or repeated use of Tobramycin Solution may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

  • Tell your doctor or dentist that you take Tobramycin Solution before you receive any medical or dental care, emergency care, or surgery.

  • Lab tests, including kidney function, hearing tests, and tobramycin levels, may be performed while you use Tobramycin Solution. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Tobramycin Solution should be used with extreme caution in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Tobramycin Solution has been shown to cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Tobramycin Solution while you are pregnant. It is not known if Tobramycin Solution is found in breast milk after inhalation. Do not breast-feed while taking Tobramycin Solution.


Possible side effects of Tobramycin Solution:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Discolored sputum; voice changes.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody stools; clumsiness; confusion; decreased hearing or other hearing changes; decreased urination; dizziness or lightheadedness; feeling of a whirling motion; fever, chills, or persistent sore throat; hearing loss; hoarseness; loss of coordination; muscle weakness; numbness or tingling; ringing or roaring in the ears; seizures; severe or persistent diarrhea; shortness of breath; stomach pain or cramps; unusual bruising or bleeding.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include decreased urination; difficulty moving the arms or legs; dizziness; hearing loss; ringing in the ears; trouble breathing; unsteadiness.


Proper storage of Tobramycin Solution:

Store Tobramycin Solution in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. If necessary, Tobramycin Solution may be stored in the foil pouches at room temperature below 77 degrees F (25 degrees C) for up to 28 days. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tobramycin Solution out of the reach of children and away from pets.


General information:


  • If you have any questions about Tobramycin Solution, please talk with your doctor, pharmacist, or other health care provider.

  • Tobramycin Solution is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tobramycin Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tobramycin resources


  • Tobramycin Use in Pregnancy & Breastfeeding
  • Tobramycin Drug Interactions
  • Tobramycin Support Group
  • 0 Reviews for Tobramycin - Add your own review/rating


Compare Tobramycin with other medications


  • Bacteremia
  • Bacterial Infection
  • Bone infection
  • Burns, External
  • Cystic Fibrosis
  • Endocarditis
  • Febrile Neutropenia
  • Intraabdominal Infection
  • Kidney Infections
  • Meningitis
  • Peritonitis
  • Pneumonia
  • Rabbit Fever
  • Sepsis
  • Shunt Infection
  • Skin Infection

Tuesday, 1 May 2012

LidoCort


Generic Name: lidocaine and hydrocortisone (Topical application route, Rectal route)


LYE-doe-kane hye-droe-KLOR-ide, hye-droe-KOR-ti-sone AS-e-tate


Commonly used brand name(s)

In the U.S.


  • AnaMantle HC

  • Lida Mantle HC

  • LidaMantle HC Relief

  • LidoCort

  • Peranex HC

Available Dosage Forms:


  • Cream

  • Pad

  • Gel/Jelly

  • Lotion

Therapeutic Class: Anesthetic Combination


Pharmacologic Class: Hydrocortisone


Chemical Class: Lidocaine


Uses For LidoCort


Lidocaine and hydrocortisone combination is used to relieve pain and itching caused by conditions such as hemorrhoids, sunburn, minor burns, insect bites or stings, poison ivy, poison oak, poison sumac, minor cuts, or scratches.


Lidocaine belongs to a group of medicines known as topical local anesthetics. It deadens the nerve endings in the skin. This medicine does not cause unconsciousness as general anesthetics do when used for surgery.


Hydrocortisone is a corticosteroid (cortisone-like medicine) that is used to relieve the redness, itching, and swelling caused by skin conditions.


This medicine is available only with your doctor's prescription.


Before Using LidoCort


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of lidocaine and hydrocortisone combination in children. However, because of this medicine's toxicity, it should be used with caution, after other medicines have been considered or found ineffective. Recommended doses should not be exceeded, and the patient should be carefully monitored during therapy.


Geriatric


No information is available on the relationship of age to the effects of lidocaine and hydrocortisone combination in geriatric patients. However, elderly patients are more likely to have age-related liver problems, which may require caution in patients receiving lidocaine and hydrocortisone combination.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Chickenpox infection or

  • Fungal infection or

  • Herpes simplex infection or

  • Liver disease, severe or

  • Tuberculosis, active—Should not be used in patients with these conditions.

  • Cushing's syndrome (adrenal gland disorder) or

  • Diabetes or

  • Hyperglycemia (high blood sugar)—Use with caution. May make these conditions worse.

  • Infection at or near the place of application or

  • Large sores, broken skin, or severe injury at the area of application—The chance of side effects may be increased.

Proper Use of lidocaine and hydrocortisone

This section provides information on the proper use of a number of products that contain lidocaine and hydrocortisone. It may not be specific to LidoCort. Please read with care.


Use this medicine exactly as directed by your doctor. Do not use it for any other condition without first checking with your doctor. This medicine may cause unwanted effects if it is used too much, because more of it is absorbed into the body through the skin.


Wash your hands with soap and water before and after using this medicine.


Unless otherwise directed by your doctor, do not apply this medicine to open wounds, burns, or broken or inflamed skin.


This medicine should only be used for problems being treated by your doctor. Check with your doctor before using it for other problems, especially if you think that an infection may be present. This medicine should not be used to treat certain kinds of skin infections or serious problems, such as severe burns.


Be careful not to get any of this medicine in your nose, mouth, ears, and especially in your eyes, because it can cause severe eye irritation. If any of the medicine does get in these areas, wash the area with water for at least 15 minutes and check with your doctor right away.


To use the Anamantle® HC kit:


  • Remove the cap from the tube of cream and firmly screw the applicator tip on to the end of the tube.

  • Squeeze the tube until a small amount of cream comes out. Lubricate the end of the applicator tip with the cream.

  • Gently insert the applicator tip with the attached tube into the anal area.

  • Continue squeezing the tube until the cream is applied to the affected areas.

  • Do not insert the applicator tip and tube completely into the anus or deep into the rectum.

  • Gently remove the applicator tip and throw it in the trash. Make sure to dispose of it out of the reach of children and pets.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For topical dosage forms (cream, lotion):
    • For pain and itching from hemorrhoids or minor skin conditions:
      • Adults—Apply a thin film to the affected area two or three times a day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using LidoCort


It is very important that your doctor check your progress at regular visits for any problems or unwanted effects that may be caused by this medicine.


If your symptoms do not improve within a few days or if they become worse, check with your doctor.


Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and for patients who use large amounts for a long time. Talk to your doctor if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.


After applying this medicine to the skin of your child, watch the child carefully to make sure that he or she does not get any of the medicine in the eyes or mouth. This medicine can cause serious side effects, especially in children, if it gets into the mouth and is swallowed.


Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.


Do not use cosmetics or other skin care products on the treated skin areas.


LidoCort Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Incidence not known
  • Burning or stinging sensation of the skin

  • paleness or redness of the skin

  • swelling of the skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: LidoCort side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More LidoCort resources


  • LidoCort Side Effects (in more detail)
  • LidoCort Use in Pregnancy & Breastfeeding
  • LidoCort Drug Interactions
  • LidoCort Support Group
  • 0 Reviews for LidoCort - Add your own review/rating


  • AnaMantle HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • LidaMantle HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Peranex HC Pad MedFacts Consumer Leaflet (Wolters Kluwer)

  • RectaGel HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Xyralid Concise Consumer Information (Cerner Multum)



Compare LidoCort with other medications


  • Hemorrhoids
  • Pruritus

Monday, 30 April 2012

Methyldopa Tablets 125mg, 250mg, 500mg (Actavis UK Ltd)





Methyldopa 125mg, 250mg and 500mg tablets




Read all of this leaflet carefully before you start to take your medicine.



  • Keep this leaflet. You may need to read it again


  • If you have any further questions, ask your doctor or pharmacist.


  • This medicine has been prescribed for you.


    Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.




Index



  • 1 What Methyldopa tablets are and what they are used for


  • 2 Before you take


  • 3 How to take


  • 4 Possible side effects


  • 5 How to store


  • 6 Further information





What Methyldopa tablets are and what they are used for



Methyldopa belongs to a group of medicines called antihypertensives, which lower blood pressure. Methyldopa tablets are used to treat high blood pressure (hypertension).





Before you take




Do not take Methyldopa tablets and tell your doctor if you:



  • are allergic (hypersensitive) to methyldopa or any of the other ingredients. (see section 6).


  • have liver disease


  • have high blood pressure due to a tumour near the kidney (phaeochromocytoma)


  • suffer from depression


  • are taking MAOIs (monoamine oxidase inhibitors) for depression.




Check with your doctor or pharmacist before taking Methyldopa tablets if you:



  • have had liver disease


  • have kidney disease


  • or a relative have a genetic/inherited disorder of the red blood pigment haemoglobin (porphyria)


  • have damaged or diseased blood vessels in your brain.




Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including
medicines obtained without a prescription. Especially:



  • alprostadil used to treat erectile dysfunction


  • NSAIDs (non-steroidal anti-inflammatory drugs) which are used to relieve pain


  • antihypertensive medicines used to treat high blood pressure (e.g. propranolol, nifedipine, verapamil or
    ‘water tablets’)


  • medicines used to treat anxiety or insomnia (e.g. diazepam, temazepam)


  • combined oral contraceptive (“the pill”) or hormone replacement therapy (HRT)


  • medicines to treat Parkinson’s disease such as levodopa, entacapone


  • linezolid (used to treat some infections)


  • lithium (used to treat depression and mental illness)


  • MAOIs (mono-amine oxidase inhibitors) used to treat depression (e.g. phenelzine)


  • medicines to treat mental illness (e.g. chlorpromazine and thioridazine)


  • moxisylyte used to treat Raynaud’s syndrome


  • muscle relaxants such as baclofen, tizanidine


  • nitrates (e.g. glycerol trinitrate “GTN”, isosorbide dinitrate/mononitrate)


  • steroids (e.g. prednisolone, hydrocortisone)


  • sympathomimetics medicines used mainly for coughs and colds (e.g. ephedrine or salbutamol)


  • medicines used to treat ulcers such as carbenoxolone


  • iron supplements.




Pregnancy and breast-feeding



If you are pregnant, planning to become pregnant or are breast-feeding ask your doctor or pharmacist for advice
before taking this medicine.





Driving and using machines



Methyldopa tablets may make you feel drowsy. Make sure you are not affected before you drive or operate
machinery.





Colourants



Each tablet contains sunset yellow (E110) which may cause allergic reactions.





Blood tests



Methyldopa may affect the results of certain laboratory tests.



Regular checks (before the start of treatment and 6-12 weeks later) may be carried out on blood cells and liver
function (blood test to show your liver is working).





Surgery



If you have to have surgery, including dental, that requires an anaesthetic let them know what medicines
you are taking.






How to take



Always take Methyldopa tablets exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.



You are advised not to drink alcohol with this medicine. Discuss this with your doctor if you have any questions.



Swallow these tablets with water.




Doses:



Adults and children over 12 years:



Initially 250mg two or three times a day, for 2 days. Then increased every 2 or more days until an adequate response is
achieved up to a maximum of 3g daily.



Children under 12 years:



Initially 10mg per kg of bodyweight daily in 2-4 divided doses adjusted as required up to 65mg/kg or 3g daily, whichever is less.



Elderly:



Initially no more than 250mg a day (e.g. 125mg twice daily), increasing up to a maximum of 2g a day.



Methyldopa may be given with, or instead of, other medicines to lower blood pressure and the doses may need to be amended.





If you take more than you should



If you (or someone else) swallow a lot of the tablets at the same time, or if you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately.



Symptoms of an overdose include excessive drowsiness, weakness, slow heart rate, low blood pressure, dizziness,
light-headedness, painful infrequent bowel movements, bloated feeling, wind, diarrhoea, feeling or being sick.





If you forget to take the tablets



Do not take a double dose to make up for a forgotten dose. If you forget to take a dose take it as soon as you remember it and then take the next dose at the right time.





If you stop taking the tablets



Do not stop treatment early because an increase in blood pressure may occur. Talk to your doctor before you stop taking the tablets and follow their advice.






Possible side effects



Like all medicines, Methyldopa tablets can cause side effects, although not everybody gets them. Please tell your doctor
or pharmacist if you notice any of the following effects or any effects not listed.




Tell your doctor if you notice any of the following side effects or notice any other effects not listed:



  • Allergic reactions: inflammation of heart muscle or the sac surrounding the heart, skin rash which may be red and/or scaly, fever.


  • Blood: your medicine may alter the numbers and types of your blood cells and cause a rise in urea in the blood. If you notice increased bruising, nosebleeds, sore throats, infections or fever, you should tell your doctor who may want to give you a blood test.


  • Endocrine system: abnormal production of milk.


  • Central nervous system: drowsiness (usually lasts a few days at start of treatment or after an increased dose), headache, loss of strength or weakness, tingling or pins and needles, trembling and shuffling walk, partial paralysis of the face, involuntary jerky movements, mental changes including nightmares, confusion, mild depression, dizziness, light-headedness, reduced blood flow to the brain.


  • Heart: slow heart rate and low blood pressure, worsening of existing angina, low blood pressure causing dizziness on standing, water retention causing swelling and weight gain.


  • Respiratory system: blocked/stuffy nose.


  • Stomach and intestines: feeling or being sick, bloated stomach, constipation, wind, diarrhoea, colitis, mild dryness of the mouth, sore or “black” tongue, inflamed salivary glands and inflammation of the pancreas (pancreatitis). Tell your doctor immediately if you get very severe abdominal pains.


  • Liver: abnormal liver function, hepatitis, jaundice (yellowing of the skin and/or whites of the eyes). These would be detected by a blood test.


  • Skin: eczema, hard skin rash (lichenoid), severe rash involving reddening, peeling and swelling of the skin that resembles severe burns (toxic epidermal necrolysis).


  • Muscles and bones: mild joint pain with or without swelling. Muscle pain or cramps.


  • Reproductive system and breasts: absence of periods, swelling of breasts in men and women, production of breast milk, failure to ejaculate, decreased sex drive, failure to maintain an erection (impotence).





How to store



Keep out of the reach and sight of children.



Store below 25°C in a dry place. Protect from light.



Do not use Methyldopa tablets after the expiry date stated on the label/carton/bottle. The expiry date refers to the last day of that month.



Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.





Further information




What Methyldopa tablets contain



  • The active substance (the ingredient that makes the tablet work) is anhydrous methyldopa. Each film-coated tablet contains either 125mg, 250mg or 500mg of the active substance.


  • The other ingredients are polyvidone, sodium edetate, magnesium stearate, crospovidone, precipitated silica, macrogol, talc, E104, E110 (sunset yellow), E132, E171, E172, E330, E460, E464.




What Methyldopa tablets look like and contents of the pack



Methyldopa tablets are yellow, circular, biconvex, film-coated tablets.



Pack size: 56





Marketing Authorisation Holder and Manufacturer




Actavis

Barnstaple

EX32 8NS

UK





This leaflet was last revised in February 2008.






Actavis

Barnstaple

EX32 8NS

UK